Microvast Holdings announces departure of chief financial officer
PALO ALTO, CA— Guardant Health , Inc. (NASDAQ:GH) director Meghan V. Joyce recently executed a sale of company stock, according to a recent SEC filing. On March 3, Joyce sold 100 shares of common stock at a price of $42.71 per share, totaling $4,271. Following this transaction, Joyce retains ownership of 7,647 shares. The sale comes as Guardant Health, with a market capitalization of $5.26 billion, has seen its stock surge over 70% in the past six months. According to InvestingPro data, the company maintains strong liquidity with a current ratio of 4.68.
The filing also reported an acquisition of 67 shares through the exercise of restricted stock units on March 4, at no cost. This transaction did not involve any financial exchange, and Joyce’s total share count increased to 7,714 following this acquisition.
These transactions are part of Joyce’s ongoing management of her equity holdings in the company.
In other recent news, Guardant Health’s fourth-quarter earnings for 2024 met expectations set in January, driven by strong growth in clinical and biopharma test volumes. The company reported $4 million in revenue from its Shield test and expects this to increase to between $25 million and $30 million in 2025. Canaccord Genuity, BTIG, and Bernstein have all raised their price targets for Guardant Health to $60, maintaining Buy or Outperform ratings, reflecting confidence in the company’s market position and growth potential. Morgan Stanley (NYSE:MS) also increased its price target to $52, maintaining an Overweight rating, suggesting a positive outlook on Guardant Health’s growth trajectory.
Guardant Health’s Reveal test, used for detecting minimal residual disease, is expected to benefit from expanded reimbursement coverage. The company has projected a 19-20% revenue increase for 2025, excluding revenue from prior periods in 2024. Bernstein noted that Guardant Health’s fourth-quarter revenues of $202 million surpassed expectations, with a gross margin of 62%, exceeding consensus estimates. The company’s guidance for 2024 includes revenues between $850 million and $860 million, with non-GAAP gross margins of 62-63%.
Despite the positive financial outlook, analysts have pointed out potential risks in 2025, particularly competition from Exact’s blood-based colorectal cancer test. However, they also identified potential positive catalysts in the screening market. Guardant Health’s commitment to its product line and strategic investments in sales and marketing are seen as key factors for its continued growth.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.